[go: up one dir, main page]

JP2003313142A - Nutrition composition - Google Patents

Nutrition composition

Info

Publication number
JP2003313142A
JP2003313142A JP2003015557A JP2003015557A JP2003313142A JP 2003313142 A JP2003313142 A JP 2003313142A JP 2003015557 A JP2003015557 A JP 2003015557A JP 2003015557 A JP2003015557 A JP 2003015557A JP 2003313142 A JP2003313142 A JP 2003313142A
Authority
JP
Japan
Prior art keywords
fatty acid
nutritional
acid
nutritional composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003015557A
Other languages
Japanese (ja)
Inventor
Tsuyoshi Nakamura
強 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2003015557A priority Critical patent/JP2003313142A/en
Publication of JP2003313142A publication Critical patent/JP2003313142A/en
Pending legal-status Critical Current

Links

Classifications

    • G06F19/00

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

(57)【要約】 【課題】通常食を摂取することが不可能な患者で、特に
高齢者や要介護者等への栄養補給の際に使用される栄養
的に優れた液状もしくは粉末栄養組成物の提供。 【解決手段】 栄養成分として、乳蛋白質、大豆蛋白
質、脂質、食物繊維、オリゴ糖、カテキン類又はポリフ
ェノール類、ビタミン、ミネラル、微量元素類を含有
し、乳蛋白質/大豆蛋白質の重量比率が0/1〜4/1であ
り、脂質中の構成脂肪酸組成がω3系脂肪酸3〜20重量%
及びω6系脂肪酸10〜40重量%であり、且つω3系脂肪
酸/ω6系脂肪酸の重量比率が1/6以上であり、水溶性食
物繊維及び/又はオリゴ糖の含有量が全固形分あたり2
〜6重量%であり、カテキン類又はポリフェノール類の
含有量が全固形分あたり0.1〜2重量%であるように栄養
組成物を調製する。
(57) [Summary] [Problem] A nutritionally excellent liquid or powdered nutrient composition used for nutritional supplementation to a patient who cannot take a normal diet, especially to the elderly or a care recipient. Offering things. SOLUTION: The nutritional component contains milk protein, soy protein, lipid, dietary fiber, oligosaccharide, catechins or polyphenols, vitamins, minerals and trace elements, and the weight ratio of milk protein / soy protein is 0 / 1 to 4/1, and the composition of fatty acids in lipids is 3 to 20% by weight of ω3 fatty acids.
And the ω6 fatty acid is 10 to 40% by weight, the weight ratio of ω3 fatty acid / ω6 fatty acid is 1/6 or more, and the content of water-soluble dietary fiber and / or oligosaccharide is 2
The nutritional composition is prepared such that the content of catechins or polyphenols is 0.1 to 2% by weight based on the total solid content.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、通常食を摂取する
ことが不可能な患者で、特に高齢者もしくは要介護者へ
の栄養補給の際に使用される液状もしくは粉末栄養組成
物に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a liquid or powder nutritional composition used for nutritional supplementation to a patient who cannot take a normal diet, particularly to an elderly person or a person requiring nursing care.

【0002】本発明は、優れた栄養効果を有し、さらに
消化管機能の劣った高齢者もしくは要介護者の腸管機能
を改善する効果、及び高齢者の輸液や経腸栄養剤などの
長期間投与に伴う心筋異常や骨萎縮を予防するととも
に、腸内菌叢の最適化による排便異常や便臭の改善効果
を有する。
[0002] The present invention has an excellent nutritional effect and also an effect of improving the intestinal tract function of an elderly person or a care recipient who has an inferior digestive tract function, and a long-term infusion or enteral nutritional supplement for the elderly person. It prevents myocardial abnormalities and bone atrophy associated with administration, and has an effect of improving defecation abnormalities and stool odors by optimizing intestinal flora.

【0003】[0003]

【従来の技術】高齢者や要介護者が健康な生活を送るた
めには種々の因子が存在するが、とりわけ栄養が大切な
問題である。この栄養管理を如何に維持するかは、高齢
者や要介護者における健康管理の大きな鍵と考えられ
る。栄養補給は、健康人であれば通常の食事を介して行
われる。このため種々の食物をバランス良く摂取するこ
とが必要である。
2. Description of the Related Art There are various factors for the elderly and care recipients to lead healthy lives, but nutrition is a particularly important issue. How to maintain this nutritional management is considered to be the key to health management for the elderly and care recipients. Nutritional support is provided through a normal diet for healthy people. Therefore, it is necessary to ingest various foods in good balance.

【0004】高齢者や要介護者における健康と疾病を考
える上で重要な栄養についての見解は、それほど明確に
は示されていない。しかし三大栄養素、ミネラル、ビタ
ミンなどの主要栄養素の必要量は明示されており、これ
に対応した栄養組成物などが供給されてきた。一方、近
年の栄養学の進展に伴って、これら主要栄養素以外の食
品中成分にも多くの生理作用が明らかにされつつある。
例えば、水溶性食物繊維(本発明では以下食物繊維と略
記する)やオリゴ糖の効果として便通改善、高脂血症予
防、腸内菌叢の最適化、腸管粘膜へのエネルギー供給な
どが明らかにされつつある。現在では食物繊維やオリゴ
糖は摂取すべき栄養成分の一つに挙げられるようになっ
てきた。
[0004] The nutritional views that are important in considering health and illness in the elderly and care recipients are not very clear. However, the required amounts of macronutrients such as the three major nutrients, minerals, and vitamins have been clearly specified, and nutritional compositions and the like corresponding to these have been supplied. On the other hand, along with the recent progress in nutritional science, many physiological actions are being clarified in food ingredients other than these macronutrients.
For example, the effects of water-soluble dietary fiber (hereinafter abbreviated as dietary fiber in the present invention) and oligosaccharides are shown to improve bowel movements, prevent hyperlipidemia, optimize intestinal flora, supply energy to intestinal mucosa, etc. Is being done. Now, dietary fiber and oligosaccharide have come to be listed as one of the nutritional components to be ingested.

【0005】また、セレンはミネラル成分の一つである
が従来の経腸栄養剤などの栄養組成物には積極的に配合
されておらず、その一方、心筋異常などの不可逆的で致
命的な欠乏症状を呈することが明らかになってきた。脂
溶性ビタミンの一つであるビタミンK類のうち、ビタミ
ンK1は従来から栄養組成物の成分として配合されてきた
が、高齢者や要介護者へ血栓塞栓症の予防のために処方
されるワルファリンの作用を減弱することが明らかにな
っている。一方、同じビタミンK類であってもビタミンK
2ではこの減弱作用の弱いことが明らかになっている。
Although selenium is one of the mineral components, it has not been positively blended in conventional nutritional compositions such as enteral nutrients, on the other hand, it is irreversible and fatal such as myocardial abnormality. It has become clear that deficiency symptoms occur. Among vitamin Ks, which are one of the fat-soluble vitamins, vitamin K 1 has been conventionally blended as a component of nutritional composition, but it is prescribed for the elderly and care recipients to prevent thromboembolism. It has been shown to diminish the effects of warfarin. On the other hand, even if it is the same vitamin K, vitamin K
In 2 , it is clear that this weakening effect is weak.

【0006】また緑茶、ウーロン茶、紅茶などの茶由来
のカテキン類やブドウ種子由来のポリフェノール類は、
消化管でのラジカルによる組織損傷等の障害を防御する
作用を有しているとともに、腸管内での異常発酵を防止
し、腸内菌叢の改善を行い便臭を軽減する効果を有する
ことが知られている。
Further, catechins derived from tea such as green tea, oolong tea and black tea and polyphenols derived from grape seeds are
It has the effect of protecting against damage such as tissue damage due to radicals in the digestive tract, and also has the effect of preventing abnormal fermentation in the intestinal tract, improving the intestinal flora and reducing stool odor. Are known.

【0007】従来、種々の栄養組成物が外科領域及び内
科領域で使用されている。これらの栄養組成物中には、
脂質や蛋白質等多くの必須栄養成分が含有されている。
特に脂質については、検討が進んでおり、極めて速やか
に消化・吸収される中鎖脂肪酸トリグリセリドやリノー
ル酸含量の高い大豆油、コーン油、サフラワー油等が主
として使用されるようになってきている。脂質の栄養成
分指標の一つである必須脂肪酸はリノール酸である。リ
ノール酸と同様にヒト体内で生合成されない必須脂肪酸
であるα−リノレン酸は、前記の油脂にはごく少量しか
含まれていない。α−リノレン酸のヒトにおける欠乏症
としては知覚異常等の神経症状や皮膚炎が報告され、さ
らに、近年ω3系列(α−リノレン酸系)の脂肪酸とそ
の代謝産物の生理機能が解明され、ω3系列代謝の出発
物質であるα−リノレン酸の役割の重要性が再認識され
てきた。すなわち、α−リノレン酸やその代謝産物であ
るエイコサペンタエン酸及びドコサへキサエン酸は血清
脂質の改善や抗血栓作用、抗炎症作用、降圧作用、免疫
抑制作用、腫瘍転移の抑制作用を有し、各種疾患の予防
・改善に期待が寄せられている。
Conventionally, various nutritional compositions have been used in the surgical and medical fields. In these nutritional compositions,
It contains many essential nutrients such as lipids and proteins.
In particular, lipids are being studied, and medium-chain fatty acid triglycerides, which are extremely rapidly digested and absorbed, soybean oil, corn oil, and safflower oil having high linoleic acid content are mainly used. . The essential fatty acid, which is one of the indicators of the nutritional components of lipids, is linoleic acid. Like the linoleic acid, α-linolenic acid, which is an essential fatty acid that is not biosynthesized in the human body, is contained in the oils and fats in a very small amount. As human deficiency of α-linolenic acid, neurological symptoms such as paresthesia and dermatitis have been reported, and in recent years, physiological functions of ω3 series (α-linolenic acid) fatty acids and their metabolites have been elucidated, and ω3 series. The importance of the role of α-linolenic acid, which is the starting material for metabolism, has been reconfirmed. That is, eicosapentaenoic acid and docosahexaenoic acid, which are α-linolenic acid and its metabolites, have serum lipid improvement and antithrombotic action, anti-inflammatory action, antihypertensive action, immunosuppressive action, and tumor metastasis inhibiting action, There are expectations for prevention and improvement of various diseases.

【0008】近年、これらの栄養に関する知見を総合し
て高齢者や要介護者の食事を検討することが行われるよ
うになってきている。しかし経管・経腸栄養剤において
はこのような配慮がなされたものは少ない。
[0008] In recent years, it has become popular to consider the diets of the elderly and care recipients by integrating these nutritional knowledge. However, there are few tube and enteral nutritional supplements with such consideration.

【0009】上述の如く、従来の栄養組成物では、脂質
の面から見るとα-リノレン酸含量が少なく、リノール
酸のみに重点がおかれて設計されているため、バランス
がとれた組成物であるとは認めがたい。また、経管栄養
法の進歩に伴い、外科手術早期から栄養組成物の使用が
可能となり、さらに在宅経管栄養法の普及とともに、経
管栄養剤の使用期間も長期化してきており、ω3系脂肪
酸/ω6系脂肪酸比のバランスの良い栄養組成物がより
一層望まれている。
As described above, the conventional nutritional composition has a low α-linolenic acid content in terms of lipids, and is designed with emphasis on linoleic acid alone. It is hard to admit. In addition, with the progress of tube feeding methods, it is possible to use nutritional compositions from the early stage of surgery, and along with the spread of home tube feeding methods, the period of use of tube feeding agents has been prolonged. A nutritional composition having a well-balanced fatty acid / ω6 fatty acid ratio is further desired.

【0010】一方、蛋白質はアミノ酸組成や蛋白価、吸
収性等を考慮し、乳蛋白質、大豆蛋白質、卵蛋白質等が
用いられている。あるいは、これらの分解物またはアミ
ノ酸もしくはこれらの組合せも用いられている。大豆蛋
白質もしくはその分解物あるいは大豆蛋白質と乳蛋白質
との組合せによる窒素源は血清脂質の改善作用、降圧作
用等を持つことが報告されている。血清脂質はリノール
酸やα-リノレン酸、エイコサペンタエン酸、ドコサヘ
キサエン酸等の多価不飽和脂肪酸により改善されること
は周知の通りであり、蛋白質など各種の窒素源と脂質と
の組合せにより、薬理的活性を有する栄養組成物を必要
としている。
On the other hand, as the protein, milk protein, soybean protein, egg protein and the like are used in consideration of amino acid composition, protein value, absorbability and the like. Alternatively, degradation products thereof or amino acids or combinations thereof have also been used. It has been reported that soybean protein or its degradation product or a nitrogen source derived from a combination of soybean protein and milk protein has a serum lipid-improving action, a hypotensive action and the like. It is well known that serum lipids are improved by polyunsaturated fatty acids such as linoleic acid, α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid. There is a need for a nutritional composition having biological activity.

【0011】更に、経口或いは経管栄養において最も頻
度の高い副作用は下痢である。特に手術施行後の施行例
においては20%前後発生する。このため、下痢は予想外
に患者および医療従事者を悩ませている大きな問題とな
っている。これまでの経口及び経管栄養組成物の開発目
標は、常に下痢発生の防止にあったと言っても過言では
ない。経口・経管栄養施行時に下痢が発生すれば、栄養
組成物の注入速度をおとす処置がとられ、最悪の場合に
は投与を中止せざるを得なくなる。この場合、患者に必
要充分な熱量を与えられないために、非生理的な静脈栄
養補給を行わざるを得なくなる。従って、下痢の発生を
抑える栄養組成物の開発は、高齢者や要介護者の栄養補
給を考える上で、早急に解決しなければならない課題で
ある。
Further, the most frequent side effect in oral or tube feeding is diarrhea. In particular, it occurs around 20% after surgery. For this reason, diarrhea has become a major problem that unexpectedly bothers patients and health care workers. It is no exaggeration to say that the development goals of oral and tube feeding compositions have always been to prevent the occurrence of diarrhea. If diarrhea occurs during oral or tube feeding, the infusion rate of the nutritional composition is controlled, and in the worst case, the administration must be discontinued. In this case, non-physiological parenteral nutrition must be performed because the patient cannot be provided with the necessary and sufficient amount of heat. Therefore, the development of a nutritional composition that suppresses the occurrence of diarrhea is an issue that must be solved immediately in consideration of nutritional supplementation for the elderly and care recipients.

【0012】本発明者は、上記の期待される栄養組成物
について鋭意検討を行ってきた。特に、主要栄養成分に
関しては、栄養学的に優れ、下痢発生防止効果を有する
栄養組成物として、ω3系脂肪酸を含有し、蛋白質とし
て大豆蛋白質を含有する栄養組成物をすでに開発し開示
している(特開平4-152861号公報)。
The inventor of the present invention has conducted extensive studies on the above expected nutritional composition. In particular, with regard to the main nutritional components, a nutritional composition which is nutritionally excellent and has an effect of preventing the occurrence of diarrhea has already been developed and disclosed which contains ω3 fatty acid and soybean protein as a protein. (Japanese Patent Laid-Open No. 4-152861).

【0013】[0013]

【発明が解決しようとする課題】本発明は、主要栄養成
分の効果に加えて、更に主要栄養素以外の成分の配合に
よって、便通改善、高脂血症予防、腸内菌叢の最適化、
腸管粘膜へのエネルギー供給などの生理効果を有する栄
養組成物の提供を課題とする。また本発明は、経口・経
管栄養剤の投与で稀に発生する致命的な欠乏症状を予防
し、高齢者や要介護者が血栓塞栓症の予防の目的で使用
されるワルファリンの効果減弱作用の少ない栄養剤の提
供を課題とする。さらに又本発明は、消化管でのラジカ
ルによる組織損傷等の障害を防御する作用を有し、かつ
便臭を軽減する効果を有する栄養組成物の提供を課題と
する。
DISCLOSURE OF THE INVENTION In addition to the effects of main nutritional components, the present invention further improves the bowel movements, prevents hyperlipidemia, and optimizes the intestinal flora by adding components other than macronutrients.
An object is to provide a nutritional composition having a physiological effect such as energy supply to the intestinal mucosa. Further, the present invention prevents the fatal deficiency symptoms that rarely occur by the administration of oral and tube feeding agents, and reduces the effect of warfarin used for the purpose of preventing thromboembolism in the elderly and care recipients. The challenge is to provide nutritional supplements with low levels. Another object of the present invention is to provide a nutritional composition having an action of protecting against damage such as tissue damage due to radicals in the digestive tract and having an effect of reducing stool odor.

【0014】[0014]

【課題を解決するための手段】本発明は、次に示す構成
である。 1.栄養成分として、乳蛋白質、大豆蛋白質、脂質、食
物繊維、オリゴ糖、カテキン類又はポリフェノール類、
ビタミン、ミネラル、微量元素を含有し、乳蛋白質/大
豆蛋白質の重量比率が0/1〜4/1であり、脂質中の構成脂
肪酸組成がω3系脂肪酸3〜20重量%及びω6系脂肪酸10
〜40重量%であり、且つ、ω3系脂肪酸/ω6系脂肪酸の
比率が1/6以上であり、水溶性食物繊維及び/又はオリ
ゴ糖の含有量が全固形分あたり2〜6重量%であり、カテ
キン類又はポリフェノール類の含有量が全固形分あたり
0.1 〜2重量%である栄養組成物。 2.ω3系脂肪酸が、α−リノレン酸、エイコサペンタ
エン酸、ドコサヘキサエン酸よりなる群から選択される
少なくとも1種の脂肪酸であり、ω6系脂肪酸がリノー
ル酸である、前記1記載の栄養組成物。 3.微量元素としてセレンを含有し、セレン含有量が栄
養組成物100kcalあたり4〜16μgである前記1又は2記
載の栄養組成物。 4.セレンが亜セレン酸塩、セレノアミノ酸又はセレン
含有微生物菌体である前記1〜3のいずれかに記載の栄
養組成物。 5.ビタミンとして、ビタミンK2を栄養組成物100kcal
あたり4〜16μg含有する前記1〜4のいずれかに記載の
栄養組成物。 6.カテキン類又はポリフェノール類が、茶由来のカテ
キン類又はブドウ種子由来のポリフェノール類である前
記1〜5のいずれかに記載の栄養組成物。
The present invention has the following configuration. 1. As a nutritional component, milk protein, soy protein, lipid, dietary fiber, oligosaccharide, catechins or polyphenols,
Contains vitamins, minerals, and trace elements, the milk protein / soy protein weight ratio is 0/1 to 4/1, and the constituent fatty acid composition in the lipid is ω3 fatty acid 3 to 20 wt% and ω6 fatty acid 10
-40% by weight, the ratio of ω3 fatty acid / ω6 fatty acid is 1/6 or more, and the content of water-soluble dietary fiber and / or oligosaccharide is 2-6% by weight based on the total solid content. , Catechins or polyphenols content per total solids
A nutritional composition which is 0.1-2% by weight. 2. 3. The nutritional composition according to 1 above, wherein the ω3 fatty acid is at least one fatty acid selected from the group consisting of α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid, and the ω6 fatty acid is linoleic acid. 3. The nutritional composition according to 1 or 2 above, which contains selenium as a trace element, and the selenium content is 4 to 16 μg per 100 kcal of the nutritional composition. 4. 4. The nutritional composition according to any one of 1 to 3 above, wherein selenium is selenite, a selenoamino acid, or a selenium-containing microbial cell. 5. As a vitamin, vitamin K 2 is a nutritional composition 100 kcal
4. The nutritional composition as described in any one of 1 to 4 above, which contains 4 to 16 μg. 6. The nutrition composition according to any one of 1 to 5 above, wherein the catechins or polyphenols are tea-derived catechins or grape seed-derived polyphenols.

【0015】[0015]

【発明の実施の形態】本発明に係る栄養組成物を構成す
る成分のうち、主要栄養成分は特定の脂質及び蛋白質を
一定の割合で組み合わせることが必要である。また、主
要成分以外の栄養成分のうち、食物繊維、オリゴ糖、微
量元素ミネラル成分の一つであるセレン、ビタミンK2
カテキン類やポリフェノール類を配合する。
BEST MODE FOR CARRYING OUT THE INVENTION Among the components constituting the nutritional composition according to the present invention, it is necessary to combine specific lipids and proteins in a fixed ratio as main nutritional components. Also, among the nutritional components other than the main components, dietary fiber, oligosaccharides, selenium, which is one of the trace element mineral components, vitamin K 2 ,
Add catechins and polyphenols.

【0016】すなわち、脂質の脂肪酸組成がω3系脂肪
酸3〜20重量%及びω6系脂肪酸10〜40重量%であり、且
つω3系脂肪酸/ω6系脂肪酸の重量比率が1/6以上であ
る脂肪酸組成の脂質を使用する。また、蛋白質として、
乳蛋白質と大豆蛋白質よりなり、両者の比率が乳蛋白質
/大豆蛋白質が0/1〜4/1の蛋白質を使用する。
That is, a fatty acid composition in which the fatty acid composition of lipid is 3 to 20% by weight of ω3 fatty acid and 10 to 40% by weight of ω6 fatty acid, and the weight ratio of ω3 fatty acid / ω6 fatty acid is 1/6 or more. Use lipids from. Also, as a protein,
The protein is composed of milk protein and soy protein, and the ratio of both is 0/1 to 4/1 milk protein / soy protein.

【0017】前記の脂質としてはω3系脂肪酸を含有す
る脂質を配合する。特に好ましいω3系脂肪酸はα-リノ
レン酸、エイコサペンタエン酸、ドコサヘキサエン酸で
あり、ω3系脂肪酸の合計が、脂肪酸組成中3〜20重量%
を含有するものを用いる。またω6系脂肪酸を含有する
脂質を配合する。特に好ましいω6系脂肪酸はリノール
酸である。このω6系脂肪酸が脂質の脂肪酸組成中10〜4
0重量%を含有しているものを用いる。ω3系脂肪酸とω
6系脂肪酸の両方を含有する油としてはシソ油、エゴマ
油、アマニ油、キリ油、魚油、サフラワー油、コーン
油、大豆油、ナタネ油などの食用油を例示しうる。これ
らの油の2種またはそれ以上を混合することによって、
本発明の構成に必要なω3/ω6比を有する脂質を得るこ
とができる。
As the above-mentioned lipid, a lipid containing an ω3 fatty acid is mixed. Particularly preferred ω3 fatty acids are α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid, and the total of ω3 fatty acids is 3 to 20% by weight in the fatty acid composition.
What contains is used. Also, a lipid containing ω6 fatty acid is added. A particularly preferred ω6 fatty acid is linoleic acid. This ω6 fatty acid is 10-4 in the fatty acid composition of lipids.
The one containing 0% by weight is used. ω3 fatty acids and ω
Examples of oils containing both 6-fatty acids include perilla oil, perilla oil, linseed oil, tung oil, fish oil, safflower oil, corn oil, soybean oil, rapeseed oil and the like. By mixing two or more of these oils,
A lipid having the ω3 / ω6 ratio necessary for the constitution of the present invention can be obtained.

【0018】蛋白質(窒素源)としては乳蛋白質と大豆
蛋白質を用い、下痢発生の防止や便性の改善、薬理学的
活性、循環器疾患、慢性疾患に対する予防効果の立場か
ら、乳蛋白質/大豆蛋白質比が0/1〜4/1とする。
Milk protein and soybean protein are used as the protein (nitrogen source), and milk protein / soybean protein is used from the standpoint of preventing diarrhea, improving faeces, pharmacological activity, cardiovascular disease, and preventive effect against chronic diseases. The protein ratio is 0/1 to 4/1.

【0019】食物繊維は果実・野菜由来の水溶性ペクチ
ン、こんにゃく・山芋由来のグルコマンナン、オーツ麦
・豆類由来のガラクトマンナン、寒天、昆布・わかめ等
海藻類由来のアルギン酸、紅藻類由来のカラギーナン等
から選択される一もしくは二以上の成分を配合する。オ
リゴ糖は、フラクトオリゴ糖、大豆オリゴ糖、ガラクト
オリゴ糖、キシロオリゴ糖等から選択される一もしくは
二以上の成分を配合する。食物繊維とオリゴ糖は、その
合計量が全固形分あたり2〜6重量%になるように配合
し、食物繊維/オリゴ糖比は4/1〜1/0に調整することが
好ましい。この数値よりオリゴ糖量が増加した場合、下
痢の発生傾向が強くなるため好ましくない。
Dietary fiber includes water-soluble pectin derived from fruits and vegetables, glucomannan derived from konjac and yam, galactomannan derived from oats and beans, alginic acid derived from seaweeds such as agar, kelp and seaweed, carrageenan derived from red algae, etc. One or more components selected from are blended. The oligosaccharide is blended with one or more components selected from fructooligosaccharide, soybean oligosaccharide, galactooligosaccharide, xylooligosaccharide and the like. It is preferable that the dietary fiber and the oligosaccharide are mixed so that the total amount thereof is 2 to 6% by weight based on the total solid content, and the dietary fiber / oligosaccharide ratio is adjusted to 4/1 to 1/0. If the amount of oligosaccharide is increased from this value, the tendency of diarrhea to occur becomes unfavorable.

【0020】本発明の栄養組成物は、微量元素であるセ
レンの含有量をコントロールしていることに特徴を有す
る。セレンは、有機又は無機形態のいずれであっても良
く、亜セレン酸塩、セレノアミノ酸、高濃度のセレン化
合物を含有する培地内で培養して得られるセレン蓄積性
を有する微生物由来のセレン含有微生物菌体を用いるこ
とができる。また、本発明の栄養組成物におけるセレン
含有量は、栄養組成物100kcalあたり4〜16μgになるよ
うに、上記セレン化合物や微生物菌体を配合する。なお
セレン含有量が16μgを超えると安全性に懸念がでてく
る。また4μg未満の場合、本発明の目的である心筋異常
などの欠乏症を予防できない。
The nutritional composition of the present invention is characterized by controlling the content of selenium, which is a trace element. Selenium may be in an organic or inorganic form, and is a selenium-containing microorganism derived from a microorganism having selenium-accumulating ability obtained by culturing in a medium containing selenium salt, selenoamino acid, and a high concentration of selenium compound. Bacteria can be used. Further, the selenium compound and microbial cells are blended so that the selenium content in the nutritional composition of the present invention is 4 to 16 μg per 100 kcal of the nutritional composition. If the selenium content exceeds 16 μg, there is concern about safety. When the amount is less than 4 μg, deficiency such as myocardial abnormality which is the object of the present invention cannot be prevented.

【0021】また本発明栄養組成物は、ビタミンKとし
てビタミンK2含量を調整した組成物であることに特徴を
有する。ビタミンK2は納豆菌など由来のメナキノン‐7
を配合することが好ましく、栄養組成物、100kcalあた
り4〜16μgを含むように配合する。16μgを超えると上
記したワーファリンの効果を減弱するなどの副作用の心
配が出てくるため好ましくない。また4μg未満の場合、
血栓塞栓症の予防効果が減弱するため好ましくない。
Further, the nutritional composition of the present invention is characterized in that the vitamin K 2 content is adjusted as vitamin K. Vitamin K 2 is derived from natto bacteria such as menaquinone-7
Is preferably blended, and the nutritional composition is blended so as to contain 4 to 16 μg per 100 kcal. If it exceeds 16 μg, side effects such as the above-mentioned effects of warfarin are diminished, which is not preferable. If less than 4 μg,
It is not preferable because the preventive effect on thromboembolism is diminished.

【0022】さらに又、本発明は消化管でのラジカルに
よる組織損傷等の障害を防御する作用を有し、かつ便臭
を軽減する効果を有するカテキン類又はポリフェノール
類を含有している栄養組成物であることに特徴を有す
る。カテキン類としては、茶由来のカテキンであってエ
ピガロカテキンガレートを10〜70重量%含むカテキン類
を用いることが好ましい。ポリフェノール類としては前
記カテキンの重合体であるタンニンやブドウ種子由来の
プロアントシアニジンを例示することができる。カテキ
ン類又はポリフェノール類の由来及び形態などは特に限
定されないが、好ましくは緑茶、ウーロン茶、紅茶など
の茶由来のもの、又はブドウ種子由来のものが好まし
い。カテキン類又はポリフェノール類は栄養組成物の全
固形分あたり0.1 〜2重量%になるように配合する。カ
テキン類又はポリフェノール類の含有量が0.1%未満の
場合は、目的とする便臭の改善効果が認められず、また
含有量が2%を超えると栄養組成物の風味低下や極端な
場合には収斂味を感じるようになるため好ましくない。
Furthermore, the present invention has a nutritional composition containing catechins or polyphenols, which has an action of protecting against damages such as tissue damage caused by radicals in the digestive tract and has an effect of reducing stool odor. It is characterized by being As the catechins, it is preferable to use catechins derived from tea and containing epigallocatechin gallate in an amount of 10 to 70% by weight. Examples of polyphenols include tannin which is a polymer of catechin and proanthocyanidins derived from grape seeds. The origin and morphology of the catechins or polyphenols are not particularly limited, but those derived from tea such as green tea, oolong tea, black tea, or those derived from grape seeds are preferred. Catechins or polyphenols are blended so as to be 0.1 to 2% by weight based on the total solid content of the nutritional composition. When the content of catechins or polyphenols is less than 0.1%, the desired effect of improving the stool odor is not observed, and when the content exceeds 2%, the flavor of the nutritional composition is deteriorated or in extreme cases. It is not preferable because it will have an astringent taste.

【0023】本発明の栄養組成物は年齢や症状などによ
り異なるが、ヒト成人一人当たり一日800kcalから2500k
calを経口的または経管・経腸的に投与することが好ま
しい。又、本発明の有効成分である大豆蛋白質、ω3系
脂肪酸を含有する油脂、水溶性食物繊維、オリゴ糖、セ
レン、ビタミンK2、カテキン類又はポリフェノール以外
の栄養成分として、蛋白質、蛋白質加水分解物、アミノ
酸、脂質、糖質、ビタミン類、ミネラル類などを配合
し、調製することができる。この時、蛋白質あるいはそ
れらの加水分解物としては、好ましくは消化・吸収に優
れ、栄養価の高いものが好ましい。例えば卵蛋白質、小
麦蛋白質、又はこれらの分解物、アミノ酸混合物を用い
てもよい。脂質としては、速やかに消化、吸収される中
鎖脂肪酸トリグリセライドなどを用いても良い。糖質と
しては、例えばデンプン、デキストリン、ショ糖、グル
コース、ガラクトース、マルトースなどが挙げられる。
ミネラルとして、Na、K、Ca、Mg、P、Cl、F
e、Zn、Cu、Mn、Iなどの有機塩又は無機塩を、
又、ビタミンとしてはビタミンA、D、E、などの脂溶
性ビタミンや、ビタミンB1 、B 2 、B6 、B12、C、
パントテン酸、ナイアシン、ビオチン、葉酸などの水溶
性ビタミンを用いる。
The nutritional composition of the present invention depends on age, symptoms, etc.
It varies from 800 kcal to 2500 k per day for each adult human
It is preferable to administer cal orally or by tube / enteral administration.
Good In addition, soybean protein which is the active ingredient of the present invention, ω3 series
Fats and oils containing fatty acids, water-soluble dietary fiber, oligosaccharides,
Len, vitamin K2, Other than catechins or polyphenols
As a nutritional ingredient of protein, protein hydrolyzate, amino
Contains acids, lipids, sugars, vitamins, minerals, etc.
Can be prepared. At this time, the protein or
The hydrolyzate of these is preferably excellent in digestion and absorption.
Therefore, those having a high nutritional value are preferable. Eg egg protein, small
Using wheat protein, or their degradation products and amino acid mixtures
May be. As a lipid, it is rapidly digested and absorbed
A chain fatty acid triglyceride or the like may be used. With sugar
For example, starch, dextrin, sucrose, glucose
Course, galactose, maltose, etc. are mentioned.
As minerals, Na, K, Ca, Mg, P, Cl, F
an organic or inorganic salt such as e, Zn, Cu, Mn or I,
As vitamins, fat-soluble vitamins A, D, E, etc.
Sex vitamins and vitamin B1 , B 2 , B6, B12, C,
Water-soluble such as pantothenic acid, niacin, biotin, folic acid
Use sex vitamins.

【0024】本発明の栄養組成物は、その形態は特に限
定されないが、例えば各有効成分及び各栄養成分を粉粉
混合して得られる粉末のもの、及び水に溶解して得られ
る液状のもの、液状のものを乾燥させて得られる粉末の
ものが好ましい。このようにして得られた栄養組成物
は、通常食を摂取することが不可能な患者や、高齢者も
しくは要介護者等への栄養補給の際に使用される。その
投与形態としては、状況に応じて経口又は経管、経腸に
て投与することができる。液状の栄養組成物の調製に当
たっては、必要に応じ、リン脂質、グリセリン脂肪酸エ
ステル、ショ糖脂肪酸エステルなどの乳化剤を用いても
良い。
Although the form of the nutritional composition of the present invention is not particularly limited, for example, a powdery product obtained by mixing each active ingredient and each nutritional ingredient into a powder, and a liquid composition obtained by dissolving in water. A powder obtained by drying a liquid is preferable. The nutritional composition thus obtained is used for nutritional supplementation to a patient who cannot ingest normal food, an elderly person or a person requiring nursing care. The form of administration may be oral, tube, or enteral depending on the situation. In preparing the liquid nutritional composition, an emulsifier such as phospholipid, glycerin fatty acid ester, sucrose fatty acid ester may be used, if necessary.

【0025】[0025]

【実施例】以下の例をもって本発明をより詳細に説明す
るが、これらは単に例示するのみであり、本発明はこれ
らによって何ら限定されるものではない。 (製造例1) 液状製剤の製造 表1に示した配合で、液状の滅菌栄養剤を常法に従い調
製した。この栄養組成物の乳蛋白質と大豆蛋白質との比
率は2/1であった。又、脂肪酸組成はカプリル酸36.5%
、α−リノレン酸9.2%、リノール酸25.9%よりなり、
ω3系脂肪酸/ω6系脂肪酸の比率は1/2.82であった。水
溶性食物繊維としてグアガム分解物を、オリゴ糖として
ガラクトシルラクトースを用い、配合量はそれぞれ固形
分あたり3.2重量%、0.8重量%であった。カテキン類と
して、茶由来のカテキンを用いた。配合量は固形分あた
り1重量%であった。セレンはセレン含有酵母菌体を用
い、セレンとして10μgとなるように配合した。又、セ
レン以外のミネラル類はNa、K、Ca、Mg、P、C
l、Feなどの有機又は無機塩混合物、ビタミンK2以外
のビタミン類はビタミンA、D、E、ビタミンB1 、B
2 、B6 、B12、C、ナイアシン、パントテン酸、葉酸
の混合物を、各々国民栄養所要量に合致した量となるよ
うに配合した。
The present invention will be described in more detail with reference to the following examples, but these are merely examples and the present invention is not limited thereto. (Production Example 1) Production of liquid preparation A liquid sterile nutrient was prepared according to a conventional method with the formulation shown in Table 1. The ratio of milk protein to soybean protein in this nutritional composition was 2/1. The fatty acid composition is 36.5% caprylic acid.
, Α-linolenic acid 9.2%, linoleic acid 25.9%,
The ratio of ω3 fatty acid / ω6 fatty acid was 1 / 2.82. A guar gum degradation product was used as the water-soluble dietary fiber and galactosyl lactose was used as the oligosaccharide, and the blending amounts were 3.2% by weight and 0.8% by weight, respectively, based on the solid content. Tea-derived catechins were used as catechins. The compounding amount was 1% by weight based on the solid content. As selenium, selenium-containing yeast cells were used, and selenium was mixed at 10 μg. Minerals other than selenium are Na, K, Ca, Mg, P, C.
1, a mixture of organic or inorganic salts such as Fe, vitamins other than vitamin K 2 are vitamins A, D, E, vitamins B 1 , B
A mixture of 2 , B 6 , B 12 , C, niacin, pantothenic acid, and folic acid was added to each of them so as to meet the national nutritional requirements.

【0026】[0026]

【表1】 [Table 1]

【0027】(製造例2) 液状製剤の製造 100mlあたり大豆油0.8g、シソ油を78.25mg(ω3系脂肪
酸/ω6系脂肪酸の比率:1/5)とした以外は製造例
1と同様にして製造した。尚、セレン及びビタミンK2
含めミネラル類及びビタミン類の組成は製造例1と同様
にした。
(Production Example 2) Production Example 2 was repeated except that 0.8 g of soybean oil and 78.25 mg of perilla oil (78% fatty acid / ω6 fatty acid ratio: 1/5) were used per 100 ml of the liquid preparation. Manufactured. The composition of minerals and vitamins including selenium and vitamin K 2 was the same as in Production Example 1.

【0028】(製造例3) 液状製剤の製造 100mlあたり乳蛋白質1.67g、大豆蛋白質3.4g(乳蛋白質
/大豆蛋白質の比率:1/2)に大豆油0g、シソ油1.21
g(ω3系脂肪酸/ω6系脂肪酸の比率:3/1)に調
製した以外、製造例1と同様に製造した。尚、セレン及
びビタミンK2も含めミネラル類及びビタミン類の組成は
製造例1と同様にした。
(Production Example 3) Production of liquid preparation: 1.67 g of milk protein, 3.4 g of soy protein (ratio of milk protein / soy protein: 1/2), 0 g of soybean oil and 1.21 of perilla oil per 100 ml.
It was produced in the same manner as in Production Example 1 except that it was adjusted to g (ratio of ω3 fatty acid / ω6 fatty acid: 3/1). The composition of minerals and vitamins including selenium and vitamin K 2 was the same as in Production Example 1.

【0029】(製造例4) 粉状製剤の製造 表2に示した配合で、粉状の本発明製剤を常法に従い調
製した。この脂質の脂肪酸組成は、α−リノレン酸3.2
%、リノール酸25.7% 、エイコサペンタエン酸7.7%、
ドコサヘキサエン酸4.5%よりなり、ω3系脂肪酸/ω6
系脂肪酸は1/1.67であった。又、乳蛋白質と大豆蛋白質
との比率は1/3であった。尚、セレン及びビタミンK2
含めミネラル類及びビタミン類の組成は製造例1と同様
にした。
(Production Example 4) Production of powdered preparation With the formulation shown in Table 2, a powdered preparation of the present invention was prepared by a conventional method. The fatty acid composition of this lipid is 3.2-α-linolenic acid.
%, Linoleic acid 25.7%, eicosapentaenoic acid 7.7%,
Docosahexaenoic acid 4.5%, ω3 fatty acid / ω6
The system fatty acid was 1 / 1.67. The ratio of milk protein to soybean protein was 1/3. The composition of minerals and vitamins including selenium and vitamin K 2 was the same as in Production Example 1.

【0030】[0030]

【表2】 [Table 2]

【0031】[0031]

【発明の効果】本発明の効果を確認するために行った試
験例を以下に示す。高齢ラットを用いた栄養状態改善効果の確認試験 本発明の構成を有する動物試験用栄養組成物を、表3を
もとに成分を調整した3種の被験栄養剤A、B、及びC
を作製し試験に用いた。又、対照栄養剤として市販の栄
養剤(エンシュアー(登録商標))D、及び、乳蛋白質
/大豆蛋白質の比率を6/1、ω3系脂肪酸/ω6系脂肪酸
の比率を10/1とし、水溶性食物繊維とオリゴ糖を8重量
%、セレンを25μg/100kcal、ビタミンK2を50μg/100
kcal、カテキンを3重量%とした栄養組成物Eを用いた。
実験に用いた各栄養剤A、B、C、Eの各栄養成分の配
合量、及び各栄養剤A〜Dの本発明に係る成分である乳
蛋白質/大豆蛋白質の比率、及びω3系脂肪酸/ω6系脂
肪酸の比率、その他の有効成分である水溶性食物繊維、
オリゴ糖、セレン、ビタミンK2、カテキン類の特性値を
表3に示す。
The test examples conducted for confirming the effects of the present invention are shown below. Confirmation test of nutritional state improving effect using aged rats Three kinds of test nutritional supplements A, B, and C in which the components of the nutritional composition for animal tests having the constitution of the present invention were adjusted based on Table 3
Was prepared and used for the test. In addition, a commercially available nutritional supplement (Ensure (registered trademark)) D as a control nutritional agent, a milk protein / soy protein ratio of 6/1, and an ω3 fatty acid / ω6 fatty acid ratio of 10/1 are water-soluble. Dietary fiber and oligosaccharides 8% by weight, selenium 25 μg / 100 kcal, vitamin K 2 50 μg / 100
A nutritional composition E containing kcal and 3% by weight of catechin was used.
The blending amount of each nutrient component of each nutrient A, B, C, E used in the experiment, the ratio of milk protein / soy protein which is the component according to the present invention of each nutrient A to D, and ω3 fatty acid / Ratio of ω6 fatty acids, other active ingredients water-soluble dietary fiber,
Table 3 shows characteristic values of oligosaccharides, selenium, vitamin K 2 and catechins.

【0032】[0032]

【表3】 [Table 3]

【0033】SD系ラットは常法に従い一日当たりの必要
エネルギー量の70%(60kcal/匹)を投与する制限給餌下
で約1年間、予備飼育した1年8ヶ月齢の高齢雄性ラット
を一群10匹、計50匹を使用した(体重358〜425g)。飼
育環境は温度23±2℃,湿度50±10%,照明7時〜19時,
換気15回/時であり、飲料水にはフィルター濾過水を与
えた。群分けは実験開始前(1年8ヶ月齢)の体重を基準
に行い、各群がほぼ均等になるように実施し、また1群n
=10匹ずつの計5群として実験を実施した。実験開始当
初から本発明製剤を含む表3の各栄養剤をラットに1日
あたり60kcalを摂取するように制限して投与し、2ヶ月
間飼育した。また、実験期間中、毎週月曜日午前中に体
重を測定した。飼育途中の7週目から3日間、採糞期間を
設けた。さらに実験最終日に全血採取して屠殺し、得ら
れた血液から血清を採取した。
The SD rats were a group of 10-year-old male rats aged 1 year and 8 months, which were preliminarily bred for about 1 year under the restricted feeding in which 70% (60 kcal / animal) of the required energy amount per day was administered according to the conventional method. A total of 50 animals were used (weight: 358 to 425 g). The breeding environment is temperature 23 ± 2 ℃, humidity 50 ± 10%, lighting 7 am-7pm,
Ventilation was 15 times / hour, and filtered water was given to drinking water. Grouping was performed based on the body weight before the start of the experiment (1 year and 8 months old), so that each group was almost even.
The experiment was carried out in 5 groups of 10 animals each. From the beginning of the experiment, each nutrient of Table 3 containing the preparation of the present invention was administered to rats while being restricted to ingest 60 kcal per day, and kept for 2 months. In addition, body weight was measured every Monday morning during the experimental period. A fecal collection period was provided for 3 days from the 7th week during the rearing. Further, on the last day of the experiment, whole blood was collected and sacrificed, and serum was collected from the obtained blood.

【0034】体重変化の測定結果を図1に示した。ま
た、栄養状態を判定する目的で、血清中のアルブミン、
総蛋白濃度、さらに、より鋭敏な栄養指標である血清中
のトランスフェリン濃度について測定し、その結果を図
2−1、2−2、2−3に示した。いずれの結果とも平
均値±標準偏差で表し、各指標の群間比較は分散分析の
多重比較法(フィッシャー検定)で行った。
The measurement results of body weight change are shown in FIG. For the purpose of determining nutritional status, albumin in serum,
The total protein concentration, and further the serum transferrin concentration, which is a more sensitive nutritional index, were measured, and the results are shown in FIGS. 2-1, 2-2, and 2-3. All results were expressed as mean value ± standard deviation, and comparison between groups of each index was performed by the multiple comparison method of analysis of variance (Fisher test).

【0035】また、採取した糞については、20名の試験
者を選定し、それぞれが臭いを官能的に評価した。検定
結果を表4に示す。各群の糞について便臭を評価し、そ
れぞれの評価項目に該当するとした試験者の人数の合計
を示している。各群間の比較はウイルコクソン検定法に
て比較した。
With respect to the collected feces, 20 testers were selected, and the smell was sensory evaluated. The test results are shown in Table 4. The fecal odor of the feces in each group was evaluated, and the total number of testers who corresponded to each evaluation item is shown. The Wilcoxon test method was used to compare the groups.

【0036】[0036]

【表4】 [Table 4]

【0037】この結果、本発明栄養剤A、B、及びCは
栄養剤D及びEに比べ、良好な体重維持効果が認められ
た。なお各栄養剤を生後4週齢のラット(1群10匹)に4
週間投与したときの体重の増加を測定したところ、有意
な差は認められなかった。また高齢ラットの血清蛋白質
を指標とした栄養評価の結果からも高齢動物の栄養状態
を良好に保つ作用を有していることが認められた。また
糞の臭いについても、本発明栄養剤A、B、及びCは栄
養剤Dに比べ、改善効果が確認された。以上の結果か
ら、本発明の栄養組成物は特に栄養状態が悪化しやすい
高齢者にとって栄養学的に優れ、便臭の改善にも優れた
組成物であることが明らかとなった。
As a result, the nutritional supplements A, B and C of the present invention were found to have a better weight-maintaining effect than the nutritional supplements D and E. Each nutritional supplement was administered to 4 week old rats (10 rats per group).
When the increase in body weight after weekly administration was measured, no significant difference was observed. In addition, the results of nutritional evaluation using serum protein of the aged rat as an index also confirmed that it has an effect of maintaining the nutritional condition of the aged animal in a good condition. Regarding the odor of feces, the nutritional supplements A, B and C of the present invention were confirmed to have an improving effect as compared with the nutrient D. From the above results, it has been clarified that the nutritional composition of the present invention is a nutritionally excellent composition especially for elderly people who are apt to deteriorate their nutritional status and is also excellent in improving stool odor.

【図面の簡単な説明】[Brief description of drawings]

【図1】高齢ラットに表3の栄養組成物を投与したときの
体重測定結果を示す。
FIG. 1 shows the results of body weight measurement when the nutritional composition of Table 3 was administered to aged rats.

【図2】高齢ラットに表3の栄養組成物を投与したときの
栄養指標の測定結果を示す。 1.血清中のアルブミン濃度を示す。 2.血清中の総蛋白濃度を示す。 3.血清中のトランスフェリン濃度を示す。
FIG. 2 shows the measurement results of nutritional indexes when the nutritional composition shown in Table 3 was administered to aged rats. 1. The albumin concentration in serum is shown. 2. The total protein concentration in serum is shown. 3. The transferrin concentration in serum is shown.

フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 3/06 A61P 3/06 7/02 7/02 9/00 9/00 9/12 9/12 19/00 19/00 29/00 29/00 35/00 35/00 37/06 37/06 Fターム(参考) 4B018 MD05 MD08 MD14 MD20 MD23 MD31 MD47 ME02 4C084 AA24 MA02 ZA361 ZA362 ZA421 ZA422 ZA541 ZA542 ZA661 ZA662 ZA961 ZA962 ZB081 ZB082 ZB111 ZB112 ZB261 ZB262 ZC211 ZC212 ZC331 ZC332 4C206 AA02 DB09 MA03 MA06 ZA36 ZA42 ZA54 ZA66 ZA96 ZB08 ZB11 ZB26 Front page continuation (51) Int.Cl. 7 Identification code FI theme code (reference) A61P 3/06 A61P 3/06 7/02 7/02 9/00 9/00 9/12 9/12 19/00 19 / 00 29/00 29/00 35/00 35/00 37/06 37/06 F term (reference) 4B018 MD05 MD08 MD14 MD20 MD23 MD31 MD47 ME02 4C084 AA24 MA02 ZA361 ZA362 ZA421 ZA422 ZA541 ZA542 ZA661 ZA662 ZA961 ZA962 ZB081 ZB082 ZB111 ZB112 ZB261 ZB262 ZC211 ZC212 ZC331 ZC332 4C206 AA02 DB09 MA03 MA06 ZA36 ZA42 ZA54 ZA66 ZA96 ZB08 ZB11 ZB26

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 栄養成分として、乳蛋白質、大豆蛋白
質、脂質、食物繊維、オリゴ糖、カテキン類又はポリフ
ェノール類、ビタミン、ミネラル、微量元素を含有し、
乳蛋白質/大豆蛋白質の重量比率が0/1〜4/1であり、脂
質中の構成脂肪酸組成がω3系脂肪酸3〜20重量%及びω
6系脂肪酸10〜40重量%であり、且つω3系脂肪酸/ω6
系脂肪酸の重量比率が1/6以上であり、水溶性食物繊維
及び/又はオリゴ糖の含有量が全固形分あたり2〜6重量
%であり、カテキン類又はポリフェノール類の含有量が
全固形分あたり0.1 〜2重量%である栄養組成物。
1. As a nutritional component, milk protein, soybean protein, lipid, dietary fiber, oligosaccharides, catechins or polyphenols, vitamins, minerals, trace elements,
The milk protein / soybean protein weight ratio is 0/1 to 4/1, and the constituent fatty acid composition in the lipid is ω3 fatty acid 3 to 20% by weight and ω
6-based fatty acid 10 to 40% by weight, and ω3 fatty acid / ω6
The weight ratio of the system fatty acid is 1/6 or more, the content of water-soluble dietary fiber and / or oligosaccharide is 2 to 6% by weight based on the total solid content, and the content of catechins or polyphenols is the total solid content. A nutritional composition which is 0.1 to 2% by weight.
【請求項2】 ω3系脂肪酸が、α−リノレン酸、エイ
コサペンタエン酸、ドコサヘキサエン酸よりなる群から
選択される少なくとも1種の脂肪酸であり、ω6系脂肪
酸がリノール酸である、請求項1記載の栄養組成物。
2. The ω3 fatty acid is at least one fatty acid selected from the group consisting of α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid, and the ω6 fatty acid is linoleic acid. Nutrition composition.
【請求項3】 微量元素としてセレンを含有し、セレン
含有量が栄養組成物100kcalあたり4〜16μgである請求
項1又は2記載の栄養組成物。
3. The nutritional composition according to claim 1, which contains selenium as a trace element, and the selenium content is 4 to 16 μg per 100 kcal of the nutritional composition.
【請求項4】 セレンが亜セレン酸塩、セレノアミノ酸
又はセレン含有微生物菌体である請求項1〜3のいずれ
かに記載の栄養組成物。
4. The nutritional composition according to claim 1, wherein the selenium is selenite, a selenoamino acid or a selenium-containing microbial cell.
【請求項5】 ビタミンとして、ビタミンK2を栄養組成
物100kcalあたり4〜16μg含有する請求項1〜4のいず
れかに記載の栄養組成物。
5. The nutritional composition according to claim 1, which contains 4 to 16 μg of vitamin K 2 per 100 kcal of the nutritional composition as a vitamin.
【請求項6】 カテキン類又はポリフェノール類が、茶
由来のカテキン類又はブドウ種子由来のポリフェノール
類である請求項1〜5のいずれかに記載の栄養組成物。
6. The nutritional composition according to claim 1, wherein the catechins or polyphenols are tea-derived catechins or grape seed-derived polyphenols.
JP2003015557A 2002-02-20 2003-01-24 Nutrition composition Pending JP2003313142A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003015557A JP2003313142A (en) 2002-02-20 2003-01-24 Nutrition composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-43852 2002-02-20
JP2002043852 2002-02-20
JP2003015557A JP2003313142A (en) 2002-02-20 2003-01-24 Nutrition composition

Publications (1)

Publication Number Publication Date
JP2003313142A true JP2003313142A (en) 2003-11-06

Family

ID=29551767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003015557A Pending JP2003313142A (en) 2002-02-20 2003-01-24 Nutrition composition

Country Status (1)

Country Link
JP (1) JP2003313142A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005261406A (en) * 2004-03-17 2005-09-29 Seisuke Tanabe Method for producing polysaccharide containing catechin
WO2005122794A1 (en) * 2004-06-17 2005-12-29 Toyo Shinyaku Co., Ltd. Composition containing plant extract and material derived from milk
EP1829553A1 (en) * 2006-02-27 2007-09-05 EnergyBalance AG Vitamins within mixtures of omega fatty acids
JP2008500032A (en) * 2004-05-25 2008-01-10 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Oral and / or topical compositions
JPWO2006082643A1 (en) * 2005-02-03 2008-06-26 太陽化学株式会社 Composition for prevention, amelioration or treatment of diabetes and / or diabetic nephropathy
WO2008006607A3 (en) * 2006-07-14 2008-10-23 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
JP2012036147A (en) * 2010-08-10 2012-02-23 En Otsuka Pharmaceutical Co Ltd Agent for improving cerebrovascular disorder
JP2013541108A (en) * 2010-10-14 2013-11-07 アーシャ ニュートリション サイエンシーズ, インコーポレイテッド Optimized nutritional formulas, methods for selecting diets tailored to them, and uses thereof
TWI450692B (en) * 2013-03-15 2014-09-01 En Otsuka Pharmaceutical Co Nutrient composition
JP2021132582A (en) * 2020-02-27 2021-09-13 森永製菓株式会社 Food and drink

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04152861A (en) * 1990-10-15 1992-05-26 Snow Brand Milk Prod Co Ltd Nutrient composition for nutrition
JPH06135838A (en) * 1992-10-30 1994-05-17 Snow Brand Milk Prod Co Ltd Oral and tubal nutrient composition
JPH10248525A (en) * 1997-03-14 1998-09-22 Taishi Shokuhin Kogyo Kk Food and drinks and feed having effect of holding and intensifying bone density or intra-bone calcium quantity
JPH1132725A (en) * 1997-07-24 1999-02-09 Mitsui Norin Kk Liquid diet
JP2001046016A (en) * 1999-08-10 2001-02-20 Ajinomoto Co Inc Yeast-incorporated mineral-enriched liquid food
JP2001316278A (en) * 2000-05-10 2001-11-13 Sanwa Kagaku Kenkyusho Co Ltd Liquid enteral nutrition composition
JP2002003388A (en) * 2000-06-20 2002-01-09 Nof Corp Constipation relief composition
JP2002029968A (en) * 2000-07-12 2002-01-29 Kikkoman Corp Proanthocyanidin composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04152861A (en) * 1990-10-15 1992-05-26 Snow Brand Milk Prod Co Ltd Nutrient composition for nutrition
JPH06135838A (en) * 1992-10-30 1994-05-17 Snow Brand Milk Prod Co Ltd Oral and tubal nutrient composition
JPH10248525A (en) * 1997-03-14 1998-09-22 Taishi Shokuhin Kogyo Kk Food and drinks and feed having effect of holding and intensifying bone density or intra-bone calcium quantity
JPH1132725A (en) * 1997-07-24 1999-02-09 Mitsui Norin Kk Liquid diet
JP2001046016A (en) * 1999-08-10 2001-02-20 Ajinomoto Co Inc Yeast-incorporated mineral-enriched liquid food
JP2001316278A (en) * 2000-05-10 2001-11-13 Sanwa Kagaku Kenkyusho Co Ltd Liquid enteral nutrition composition
JP2002003388A (en) * 2000-06-20 2002-01-09 Nof Corp Constipation relief composition
JP2002029968A (en) * 2000-07-12 2002-01-29 Kikkoman Corp Proanthocyanidin composition

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005261406A (en) * 2004-03-17 2005-09-29 Seisuke Tanabe Method for producing polysaccharide containing catechin
JP2008500032A (en) * 2004-05-25 2008-01-10 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Oral and / or topical compositions
WO2005122794A1 (en) * 2004-06-17 2005-12-29 Toyo Shinyaku Co., Ltd. Composition containing plant extract and material derived from milk
US8029829B2 (en) 2005-02-03 2011-10-04 Taiyo Kagaku Co., Ltd. Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy
JPWO2006082643A1 (en) * 2005-02-03 2008-06-26 太陽化学株式会社 Composition for prevention, amelioration or treatment of diabetes and / or diabetic nephropathy
EP1829553A1 (en) * 2006-02-27 2007-09-05 EnergyBalance AG Vitamins within mixtures of omega fatty acids
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
JP2009544590A (en) * 2006-07-14 2009-12-17 ナットファルマ エーエスエー Medicines and nutritional supplements containing vitamin K2
EP2046312A2 (en) 2006-07-14 2009-04-15 NattoPharma ASA Pharmaceutical and nutraceutical products comprising vitamin k2
WO2008006607A3 (en) * 2006-07-14 2008-10-23 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
JP2014031378A (en) * 2006-07-14 2014-02-20 Nattopharma Asa Pharmaceutical comprising vitamin k2 and nutritional supplement product
NO343923B1 (en) * 2006-07-14 2019-07-08 Pharmaco As Pharmaceutical and nutraceutical products which include at least one compound within the vitamin K2 class and such products for the prevention or therapy of disorders related to bone, cartilage and the cardiovascular system.
JP2012036147A (en) * 2010-08-10 2012-02-23 En Otsuka Pharmaceutical Co Ltd Agent for improving cerebrovascular disorder
JP2013541108A (en) * 2010-10-14 2013-11-07 アーシャ ニュートリション サイエンシーズ, インコーポレイテッド Optimized nutritional formulas, methods for selecting diets tailored to them, and uses thereof
EP2627197A4 (en) * 2010-10-14 2017-05-24 Asha Nutrition Sciences, Inc. Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof
JP2018005928A (en) * 2010-10-14 2018-01-11 アーシャ ニュートリション サイエンシーズ, インコーポレイテッド Optimized nutritional formulations, methods for selecting tailored diets therefrom, and using methods thereof
TWI450692B (en) * 2013-03-15 2014-09-01 En Otsuka Pharmaceutical Co Nutrient composition
JP2021132582A (en) * 2020-02-27 2021-09-13 森永製菓株式会社 Food and drink
JP7575877B2 (en) 2020-02-27 2024-10-30 森永製菓株式会社 Food and Drink

Similar Documents

Publication Publication Date Title
JP3545760B2 (en) Nutritional composition for controlling blood sugar level
Spaeth et al. Bulk prevents bacterial translocation induced by the oral administration of total parenteral nutrition solution
DE502007010071C5 (en) USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL
JP6285108B2 (en) Probiotics in pre-operative and / or post-operative environments
DE60033233T2 (en) FOOD SUPPLEMENTS
US20030194423A1 (en) Composition for enhancing nutritional content of food
JP4553604B2 (en) Function enhancing composition for general food, health functional food or health supplement and method thereof
JP2012197293A (en) Total enteral nutritious composition
US20220030909A1 (en) Intact Pea Protein-Based Nutrient Composition
US12329795B2 (en) Composition for weight reduction and body fat reduction, preparation method and application thereof
JP2003313142A (en) Nutrition composition
WO1998018346A2 (en) Neutral-tasting microcapsules, method for their manufacturing and their use
JP2003113089A (en) Chitosan-containing preparations and foods and drinks having lipid accumulation inhibition and cholesterol lowering action
EP1616570A1 (en) Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
JP2012036147A (en) Agent for improving cerebrovascular disorder
JPWO2016052509A1 (en) Renal failure progression inhibitor, renal failure prevention agent, and indoxyl sulfate production inhibitor
US20010047036A1 (en) Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
KR100484326B1 (en) Foods containing cocoa component
JP2004041006A (en) Liquid nutrition composition
TWI450692B (en) Nutrient composition
NZ519932A (en) Formulations comprising arachidonic acid (AA) and docosahexanoic acid (DHA) in nutritionally complete beverages
JP2004285007A (en) Deodorizing component-containing nutritive composition
DE29623285U1 (en) Tasteless microcapsules and food or feed containing them
CN115918898A (en) Clostridium butyricum-containing diabetes total-nutrient formula food and preparation method and application thereof
Scolapio et al. 7 Malnutrition: Vitamin and Trace Mineral

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091006

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091013

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091013

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091113

A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100115

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100226